Neoadjuvant Durvalumab Improves Survival in Early TNBC Independent of Pathological Complete Response
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
Ann. Oncol 2022 Aug 09;[EPub Ahead of Print], S Loibl, A Schneeweiss, J Huober, M Braun, J Rey, JU Blohmer, J Furlanetto, DM Zahm, C Hanusch, J Thomalla, C Jackisch, P Staib, T Link, K Rhiem, C Solbach, PA Fasching, V Nekljudova, C Denkert, M UntchFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.